Roche
Roche secures CE Mark for automated latent tuberculosis blood test
July 14, 2026Research and Development Roche, tuberculosis infection
Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood test designed to improve the …
Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory
March 25, 2026Research and Development AI, NVIDIA, Roche
Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance graphics processing units (GPUs) across …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
July 30, 2025Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Roche advances treatment for Parkinson’s disease
June 16, 2025Research and Development Neurology, Parkinson's disease, Roche, clinical trials, neurodegenerative disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s …
Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy
June 5, 2025Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)
Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Roche gains CE Mark for AI glucose monitoring system for diabetes management
July 9, 2024Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring
Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.
FDA approves Roche’s HPV self-collection screening option
May 15, 2024Medical Communications FDA, HPV, Oncology, Roche, cervical cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
March 20, 2024Manufacturing and Production Lonza, Pharmacy, Roche, biologics, facility, manufacturing
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics site based in Vacaville, California, …
Roche shares data on novel solution for continuous glucose monitoring
March 8, 2024Research and Development Diabetes, Medical device, Roche, continuous glucose monitoring, diabetes
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), including a CGM sensor and …
Roche shares data from phase 3 trial of Xolair as allergy treatment
February 26, 2024Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
Roche to acquire Carmot Therapeutics for $2.7bn
December 4, 2023Business Services Obesity, Roche, acquisition, diabetes
Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
